Table 2.
Patient demographics and clinical characteristics.
| Demographics | |
|---|---|
| Female (n, %) | 53 (57 %) |
| Age [mean (SD)] | 32.6 (10.2) |
| Pregnancy (n, % of female) | 4 (7.5 %) |
| Days of symptoms before admission [median (IQR)] | 4 (3−5) |
| Antibiotic use during disease course (n, %) | 55 (59.8 %) |
| Ribavirin (n, %) | 8 (8.6 %) |
| Vaccination status (n, %) | |
| None | 12 (12.9 %) |
| Incomplete | 25 (26.9 %) |
| Unknown | 56 (60.2 %) |
| Ethnicity (n, %) | |
| Non-Greek | 19 (20.4 %) |
| Greek | 74 (79.6 %) |
| Roma ethnic subgroup (% of Greek patients) | 11 (14.9 %) |
| Comorbidities (n, %) | |
| None | 81 (87 %) |
| Diabetes | 4 (4.3 %) |
| Chronic pulmonary disease | 6 (6.5 %) |
| Coronary artery disease | 5 (5.4 %) |
| Heart failure | 2 (2.2 %) |
| Current cancer | 0 (0%) |
| Cirrhosis | 1 (1.1 %) |
| Symptoms and signs, n (%) | |
| Rash | 89 (95.7 %) |
| Cough | 52 (55.9 %) |
| Koplik spots | 30 (34.1 %) |
| GI symptoms | 29 (31.9 %) |
| Pharyngitis | 28 (30.1 %) |
| Conjunctivitis | 27 (29 %) |
| Nasal discharge | 16 (17.2 %) |
| Lymphadenopathy | 14 (16.1 %) |
| Dyspnea | 10 (10.8 %) |
| Complications, n (%) | |
| Pneumonitis | 43 (46.2 %) |
| Hepatic involvement | 75 (80.5 %) |
| Grade I | 47 (50.5 %) |
| Grade II | 28 (30.2 %) |
| Outcomes | |
| Discharged (n, %) | 92 (98.9 %) |
| Died (n, %) | 1 (1.1 %) |
| Hospitalization in days [median (IQR)] |
6 (4−7) |
GI: gastrointestinal, IQR: interquartile range, n: number of patients, SD: standard deviation.